Literature DB >> 22477494

Atherosclerosis in sickle cell disease - a review.

Mohamed A Elsharawy1, Khaled M Moghazy, Mohamed A Shawarby.   

Abstract

Acute, vaso-occlusive crises are the most common and earliest clinical manifestations of sickle cell disease. Recent thoughts about development of atherosclerosis as a result of this disease are presented. Current insights into the pathogenesis of atherosclerosis in sickle cell disease are reviewed, in particular the role of endothelial dysfunction, homocysteine and platelets. Common and uncommon sites of atherosclerosis are described. Radiological assessment and potential therapeutic agents to slow the progression of atherosclerosis are discussed. Finally, treatment of atherosclerosis in certain sites is evaluated and reviewed.

Entities:  

Year:  2009        PMID: 22477494      PMCID: PMC2780857          DOI: 10.1055/s-0031-1278326

Source DB:  PubMed          Journal:  Int J Angiol        ISSN: 1061-1711


  52 in total

Review 1.  Pulmonary hypertension associated with sickle cell disease: pathophysiology and rationale for treatment.

Authors:  Raymond L Benza
Journal:  Lung       Date:  2008-05-10       Impact factor: 2.584

Review 2.  Sickle cell disease: imaging of cerebrovascular complications.

Authors:  C J Moran; M J Siegel; M R DeBaun
Journal:  Radiology       Date:  1998-02       Impact factor: 11.105

3.  Occlusion of large cerebral vessels in sickle-cell anemia.

Authors:  J A Stockman; M A Nigro; M M Mishkin; F A Oski
Journal:  N Engl J Med       Date:  1972-10-26       Impact factor: 91.245

4.  Sickle cell acute chest syndrome: pathogenesis and rationale for treatment.

Authors:  M J Stuart; B N Setty
Journal:  Blood       Date:  1999-09-01       Impact factor: 22.113

Review 5.  Endothelial cell responses to hypoxic stress.

Authors:  D V Faller
Journal:  Clin Exp Pharmacol Physiol       Date:  1999-01       Impact factor: 2.557

Review 6.  Prostanoid therapy for pulmonary arterial hypertension.

Authors:  David B Badesch; Vallerie V McLaughlin; Marion Delcroix; Carmine Dario Vizza; Horst Olschewski; Olivier Sitbon; Robyn J Barst
Journal:  J Am Coll Cardiol       Date:  2004-06-16       Impact factor: 24.094

7.  Large-vessel occlusion in sickle cell disease: pathogenesis, clinical consequences, and therapeutic implications.

Authors:  R B Francis
Journal:  Med Hypotheses       Date:  1991-06       Impact factor: 1.538

8.  Hyperhomocysteinemia as a risk factor for deep-vein thrombosis.

Authors:  M den Heijer; T Koster; H J Blom; G M Bos; E Briet; P H Reitsma; J P Vandenbroucke; F R Rosendaal
Journal:  N Engl J Med       Date:  1996-03-21       Impact factor: 91.245

Review 9.  Sickle cell lung disease and sudden death: a retrospective/prospective study of 21 autopsy cases and literature review.

Authors:  Jason K Graham; Marina Mosunjac; Randy L Hanzlick; Mario Mosunjac
Journal:  Am J Forensic Med Pathol       Date:  2007-06       Impact factor: 0.921

10.  Nitric oxide inhibition of endothelial cell mitogenesis and proliferation.

Authors:  R Sarkar; R C Webb; J C Stanley
Journal:  Surgery       Date:  1995-08       Impact factor: 3.982

View more
  9 in total

1.  Paradoxical protection from atherosclerosis and thrombosis in a mouse model of sickle cell disease.

Authors:  Hui Wang; Wei Luo; Jintao Wang; Chiao Guo; Stephanie L Wolffe; Julia Wang; Eddy B Sun; Kori N Bradley; Andrew D Campbell; Daniel T Eitzman
Journal:  Br J Haematol       Date:  2013-04-17       Impact factor: 6.998

2.  Depletion of haptoglobin and hemopexin promote hemoglobin-mediated lipoprotein oxidation in sickle cell disease.

Authors:  Ayla Yalamanoglu; Jeremy W Deuel; Ryan C Hunt; Jin Hyen Baek; Kathryn Hassell; Katie Redinius; David C Irwin; Dominik J Schaer; Paul W Buehler
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-07-26       Impact factor: 5.464

3.  Plasma chitotriosidase and carotid intima-media thickness in children with sickle cell disease.

Authors:  Normeen A Kaddah; Dalia A Saied; Hanan A Alwakeel; Rania H Hashem; Sara M Rowizak; Mohamed A Elmonem
Journal:  Int J Hematol       Date:  2017-07-04       Impact factor: 2.490

4.  [Heart rate-dependent ECG changes in a patient with severe sickle cell disease].

Authors:  Konrad Peukert; Sven Klaschik; Tobias Hilbert
Journal:  Anaesthesist       Date:  2021-03-16       Impact factor: 1.041

5.  Vasculo-toxic and pro-inflammatory action of unbound haemoglobin, haem and iron in transfusion-dependent patients with haemolytic anaemias.

Authors:  Francesca Vinchi; Richard Sparla; Sara T Passos; Richa Sharma; S Zebulon Vance; Hala S Zreid; Hesham Juaidi; Deepa Manwani; Karina Yazdanbakhsh; Vijay Nandi; André M N Silva; Anand R Agarvas; Eitan Fibach; John D Belcher; Gregory M Vercellotti; Husam Ghoti; Martina U Muckenthaler
Journal:  Br J Haematol       Date:  2021-03-15       Impact factor: 6.998

6.  Arterial stiffness and pulse wave reflection in young adult heterozygous sickle cell carriers.

Authors:  Tünzale Bayramoğlu; Oğuz Akkuş; Kamil Nas; Miklós Illyes; Ferenc Molnar; Emel Gürkan; M Bayram Bashırov; Serafettin Demir; Gamze Akkuş; Esmeray Acartürk
Journal:  Turk J Haematol       Date:  2013-12-05       Impact factor: 1.831

Review 7.  Atherogenesis and iron: from epidemiology to cellular level.

Authors:  Francesca Vinchi; Martina U Muckenthaler; Milene C Da Silva; György Balla; József Balla; Viktória Jeney
Journal:  Front Pharmacol       Date:  2014-05-05       Impact factor: 5.810

8.  Quercetin reduces hydroxyurea induced cytotoxicity in immortalized mouse aortic endothelial cells.

Authors:  Zachary M Kiser; Monica D M McGee; Racquel J Wright; Alexander Quarshie; Gale W Newman; Karen R Randall; Jonathan K Stiles; Adel Driss; Jacqueline M Hibbert
Journal:  PeerJ       Date:  2017-05-31       Impact factor: 2.984

9.  Acacia Senegal (Gum Arabic) Supplementation Modulate Lipid Profile and Ameliorated Dyslipidemia among Sickle Cell Anemia Patients.

Authors:  Lamis Kaddam; Imad Fadl-Elmula; Omer Ali Eisawi; Haydar Awad Abdelrazig; Amal M Saeed
Journal:  J Lipids       Date:  2019-06-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.